Opinion - How many drug targets are there?

被引：2652

作者：

Overington, John P.

Al-Lazikani, Bissan

Hopkins, Andrew L.

机构：

[1] Inpharmat Ltd, London WC1A 1NU, England

[2] Pfizer Ltd, Global Res & Dev, Sandwich CT13 9NJ, Kent, England

来源：

NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 12期

关键词：

D O I：

10.1038/nrd2199

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

For the past decade, the number of molecular targets for approved drugs has been debated. Here, we reconcile apparently contradictory previous reports into a comprehensive survey, and propose a consensus number of current drug targets for all classes of approved therapeutic drugs. One striking feature is the relatively constant historical rate of target innovation ( the rate at which drugs against new targets are launched); however, the rate of developing drugs against new families is significantly lower. The recent approval of drugs that target protein kinases highlights two additional trends: an emerging realization of the importance of polypharmacology, and also the power of a gene-family-led approach in generating novel and important therapies.

引用

页码：993 / 996

页数：4

共 26 条

[1] Kinase inhibition with BAY 43-9006 n renal cell carcinoma [J].

Ahmad, T ;

Eisen, T .

CLINICAL CANCER RESEARCH, 2004, 10 (18) :6388S-6392S

[2] A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase [J].

Atwell, S ;

Adams, JM ;

Badger, J ;

Buchanan, MD ;

Feil, IK ;

Froning, KJ ;

Gao, X ;

Hendle, J ;

Keegan, K ;

Leon, BC ;

Müller-Dieckmann, HJ ;

Nienaber, VL ;

Noland, BW ;

Post, K ;

Rajashankar, KR ;

Ramos, A ;

Russell, M ;

Burley, SK ;

Buchanan, SG .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (53) :55827-55832

[3]

Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkp985, 10.1093/nar/gkr1065, 10.1093/nar/gkh121]

[4] The Protein Data Bank [J].

Berman, HM ;

Westbrook, J ;

Feng, Z ;

Gilliland, G ;

Bhat, TN ;

Weissig, H ;

Shindyalov, IN ;

Bourne, PE .

NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242

[5]

Christensen C. M., 1997, INNOVATORS DILEMMA N

[6] The role of innovation in drug development [J].

Drews, J ;

Ryser, S .

NATURE BIOTECHNOLOGY, 1997, 15 (13) :1318-1319

[7] Genomic sciences and the medicine of tomorrow [J].

Drews, J .

NATURE BIOTECHNOLOGY, 1996, 14 (11) :1516-&

[8] Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells [J].

Druker, BJ ;

Tamura, S ;

Buchdunger, E ;

Ohno, S ;

Segal, GM ;

Fanning, S ;

Zimmermann, J ;

Lydon, NB .

NATURE MEDICINE, 1996, 2 (05) :561-566

[9] A small molecule-kinase interaction map for clinical kinase inhibitors [J].

Fabian, MA ;

Biggs, WH ;

Treiber, DK ;

Atteridge, CE ;

Azimioara, MD ;

Benedetti, MG ;

Carter, TA ;

Ciceri, P ;

Edeen, PT ;

Floyd, M ;

Ford, JM ;

Galvin, M ;

Gerlach, JL ;

Grotzfeld, RM ;

Herrgard, S ;

Insko, DE ;

Insko, MA ;

Lai, AG ;

Lélias, JM ;

Mehta, SA ;

Milanov, ZV ;

Velasco, AM ;

Wodicka, LM ;

Patel, HK ;

Zarrinkar, PP ;

Lockhart, DJ .

NATURE BIOTECHNOLOGY, 2005, 23 (03) :329-336

[10]

GOLDEN J, 2003, CURR DRUG DISCOV FEB, P17

← 1 2 3 →